Wellinks, a New Haven-based cardiopulmonary care company, announced the first close of its Series B funding, securing $10 million with participation from UMass Memorial Health and inside investors to accelerate its predictive care model.

The investment builds on Wellinks' multiyear relationship with UMass Memorial Health and other partners. Wellinks' FDA-cleared Spire Remote Patient Monitoring (RPM) System identifies early physiologic changes associated with clinical deterioration, supporting earlier intervention for chronic respiratory disease. Its Health Tags offer passive, continuous monitoring that predicts clinical deterioration up to one week before a patient feels symptom onset.

Wellinks and UMass Chan Medical School previously collaborated on the Healthy at Home program to reduce acute care utilization in COPD patients. The study found participants had more than 60% lower odds of 30-day hospital readmission, with trends toward fewer emergency department visits and shorter hospital stays than non-participating patients.

Dr. Eric Dickson, CEO at UMass Memorial Health, said, "Our continued collaboration with Wellinks reflects a shared commitment to advancing proactive, data-driven care. Together, we're generating real-world clinical evidence that supports better outcomes for patients and informs the future of cardiopulmonary care."

Wellinks will use the funding to expand its commercial footprint into rural and underserved communities, strengthen its predictive capabilities using real-world clinical data, and expand into additional cardiopulmonary conditions, including congestive heart failure.

"This investment represents validation of the solution we've built and the outcomes it delivers," said Jennifer Barretta, Chief Operating Officer and Interim CEO of Wellinks. "Our approach aims to close care gaps for patients, including those at risk for poor adherence, leading to lower healthcare utilization and a reduced cost of care."